Albany, NY -- (SBWIRE) -- 12/03/2015 -- The global anxiety disorders and depression treatment market will decline at a moderate CAGR of 1.25% during the forecast period from 2014 to 2020. In 2013, the global anxiety disorders and depression treatment market was worth US$22.5 bn and by 2020, the market is expected to shrink to US$18.2 bn.

The global anxiety disorders and depression treatment market is driven by the rising prevalence of depression and anxiety disorders. According to the WHO, presently, around 350 mn people are affected by depression. The global anxiety disorders and depression treatment market's growth will also be encouraged by the reduced side effects and increased efficacy of drugs in various classes. Demand from the rising geriatric population will further fuel the global anxiety disorders and depression treatment market, as anxiety and depression are commonly observed in the geriatric population.

Download Sample Report:-http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

The global anxiety disorders and depression treatment market will demonstrate a moderate growth curve challenged by several market trends. The patent expiration of major drugs, growing number of generic drug variants, dry pipeline of novel drugs, and rising prevalence of drug-resistant mental disorders will challenge the growth of the global anxiety disorders and depression treatment market. Nevertheless, the improving distribution network in emerging economies will provide a good growth opportunity for players operating in the global anxiety disorders and depression treatment market.

On the basis of drug class, the global anxiety disorders and depression treatment market is segmented into atypical antipsychotics, monoamine oxidase inhibitors (MAOIs), beta blockers, anticonvulsants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and tetracyclic antidepressants (TeCAs). In 2013, the global anxiety disorders and depression treatment market was led by SNRIs. The SNRIs segment held a share of ~30% in the global anxiety disorders and depression treatment market in 2013. Some of the top drugs in the pipeline in the global anxiety disorders and depression treatment market are ALKS-5461, brexpiprazole (OPC-34712), and Brintellix (vortioxetine - Lu AA21004).

Region-wise, the global anxiety disorders and depression treatment market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America dominates the global anxiety disorders and depression treatment market due to the presence of a large patient population suffering from various anxiety disorders. The U.S. anxiety disorders and depression treatment market has reached saturation and many antidepressant drugs are available on prescription for the same symptom. Hence, players in the U.S. anxiety disorders and depression treatment market are focusing on introducing more effective drugs for new symptoms. Asia Pacific will experience moderate growth in the global anxiety disorders and depression treatment market due to demand from large emerging economies such as China and Japan.

A growing number of companies are focusing on providing herbal drugs to answer the rising demand from consumers for safer, natural drugs. Some of the key players operating in the global anxiety disorders and depression treatment market are Sanofi-Aventis, Pfizer, Johnson & Johnson, Eli Lilly and Company, and AstraZeneca.

Key Segments of the Global Anxiety Disorders and Depression Treatment Market
Anxiety Disorders and Depression Treatment Market, by Drug Class
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antipsychotics
Tricyclic Antidepressants (TCAs)
Tetracyclic Antidepressants (TeCAs)
Monoamine Oxidase inhibitors (MAOIs)
Benzodiazepines
Beta-Blockers
Anticonvulsants

Anxiety Disorders and Depression Treatment Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

Browse Full Report With TOC: http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr. Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com